RxDoctor Payments Data

Richard Friedman, MD

Cardiovascular Disease · San Diego, CANPI 1881789196

Payments from drug & device makers

$3,381in general payments, 2019–2025

Across 172 payments — averaging $19.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$843
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$559
  • Pfizer$263
  • AOP Health US, LLC$223
  • Merck$218
  • Actelion Pharmaceuticals US, Inc.$190
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$3,381100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,381 in reported general payments places this provider in the 50th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$113,704
Medicare patients
800
Services billed
2,138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban112$155,537
EliquisApixaban122$135,800
EntrestoSacubitril/Valsartan26$34,538
JardianceEmpagliflozin17$17,004
BrilintaTicagrelor11$9,114
Pindolol34$3,559
Metoprolol Succinate214$3,122
Atorvastatin Calcium215$2,411
Diltiazem 24hr Er (Cd)Diltiazem Hcl32$1,753
Potassium Chloride56$1,308
ClopidogrelClopidogrel Bisulfate66$869
Warfarin Sodium69$821
Flecainide Acetate12$815
Metoprolol Tartrate111$670
Rosuvastatin Calcium64$640

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$79$155,537112 claims
PfizerEliquis$263$135,800122 claims
NovartisEntresto$843$34,53826 claims
Boehringer IngelheimJardiance$43$17,00417 claims
AstraZenecaBrilinta$156$9,11411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →